Alivus Life Sciences
ALIVUSNSE

Alivus Life Sciences

₹1,039.00-17.50 (1.66%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,030.40
Today’s high
1,073.20
52 week low
819.00
52 week high
1,148.40
Open price
1,073.20
Previous close
1,056.50
Live volume
84,154
Lower circuit
831.20
Upper circuit
1,246.80

Fundamentals

Market Cap
₹12,715Cr
ROE
16.94%
P/E Ratio(TTM)
22.53
EPS(TTM)
45.99
P/B Ratio
3.82
Dividend Yield
0.48%
Industry P/E
44.45
Book Value
271.48
Debt to Equity
0.02
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹712
+3.65%
Profit (Cr)
₹163
+8.25%
0200400600800
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+8%
3Y CAGR+4%
Profit growthValue
1Y (TTM)+15%
3Y CAGR+5%

About

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) is a leading developer and manufacturer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas.;
CEO/MD
Dr. Yasir Rawjee
Founded in
2011
NSE symbol
ALIVUS

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
74.87%
Retail And Others
12.56%
Mutual Funds
5.63%
Foreign Institutions
5.29%
Other Domestic Institutions
1.64%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹1,343.80
-42.10 (3.04%)
L
    H
    18,628.2928.774.77
    ₹751.95
    -12.25 (1.60%)
    L
      H
      18,624.4231.33.66
      ₹1,006.35
      -5.30 (0.52%)
      L
        H
        16,021.6040.312.43
        Concord BiotechCONCORDBIO
        ₹1,153.30
        +30.00 (2.67%)
        L
          H
          12,070.6238.86.61
          Livesquawk
          Alivus Life Sciences Q4 EBITDA rises to ₹2.1B vs ₹1.98B YoY. EBITDA margin improves to 31.1% from 30.6%, up 0.6 pp YoY.
          Livesquawk
          A fire at Alivus Life Sciences' API plant in Dahej injured three people. The company is investigating the cause, assessing damages, and has sufficient insurance.
          Livesquawk
          Alivus Life Sciences aims to conclude 1-2 CDMO projects by Q1 FY27. The company projects double-digit growth for FY28-29.
          2026
          14
          May
          Annual Result
          Release date
          22
          Jan
          Quarterly Result
          Release date
          2025
          6
          Nov
          Quarterly Result
          Release date

          1
          Sep
          Dividend
          Ex date
          ₹5.00
          per share

          For each share you hold, you will receive ₹5.00
          Dividend amount₹5.00 per share
          Dividend TypeFinal
          Ex Date1 Sep ‘25
          Record Date1 Sep ‘25
          Announcement date15 May ‘25
          1
          Aug
          Quarterly Result
          Release date

          15
          May
          Dividend
          Announced
          ₹5.00
          per share

          For each share you hold, you will receive ₹5.00
          Dividend amount₹5.00 per share
          Dividend TypeFinal
          Ex Date1 Sep ‘25
          Record Date1 Sep ‘25
          Announcement date15 May ‘25
          Events calendar
          View upcoming events in other stocks